1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Autoinjectors Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Autoinjectors Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancement
5.2. Disease Incidence and Prevalence
5.3. Overview: Future of Autoinjectors
5.4. Regulatory Analysis
5.5. COVID-19 Impact Analysis
6. Global Autoinjectors Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Disposable
6.3.2. Reusable
6.4. Market Attractiveness Analysis, by Type
7. Global Autoinjectors Market Analysis and Forecast, by Technology
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Technology, 2017-2031
7.3.1. Handheld
7.3.2. Wearable
7.4. Market Attractiveness Analysis, by Technology
8. Global Autoinjectors Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
8.3.1. Subcutaneous
8.3.2. Intramuscular
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Autoinjectors Market Analysis and Forecast, by Indication
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Indication, 2017-2031
9.3.1. Multiple Sclerosis
9.3.2. Rheumatoid Arthritis
9.3.3. Diabetes
9.3.4. Anaphylaxsis
9.3.5. Others
9.4. Market Attractiveness Analysis, by Indication
10. Global Autoinjectors Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by End-user, 2017-2031
10.3.1. Homecare Settings
10.3.2. Hospitals & Clinics
10.4. Market Attractiveness Analysis, by End-user
11. Global Autoinjectors Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Autoinjectors Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
12.2.1. Disposable
12.2.2. Reusable
12.3. Market Value Forecast, by Technology, 2017-2031
12.3.1. Handheld
12.3.2. Wearable
12.4. Market Value Forecast, by Route of Administration, 2017-2031
12.4.1. Subcutaneous
12.4.2. Intramuscular
12.5. Market Value Forecast, by Indication, 2017-2031
12.5.1. Multiple Sclerosis
12.5.2. Rheumatoid Arthritis
12.5.3. Diabetes
12.5.4. Anaphylaxsis
12.5.5. Others
12.6. Market Value Forecast, by End-user, 2017-2031
12.6.1. Homecare Settings
12.6.2. Hospitals & Clinics
12.7. Market Value Forecast, by Country, 2017-2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Type
12.8.2. By Technology
12.8.3. By Route of Administration
12.8.4. By Indication
12.8.5. By End-user
12.8.6. By Country
13. Europe Autoinjectors Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
13.2.1. Disposable
13.2.2. Reusable
13.3. Market Value Forecast, by Technology, 2017-2031
13.3.1. Handheld
13.3.2. Wearable
13.4. Market Value Forecast, by Route of Administration, 2017-2031
13.4.1. Subcutaneous
13.4.2. Intramuscular
13.5. Market Value Forecast, by Indication, 2017-2031
13.5.1. Multiple Sclerosis
13.5.2. Rheumatoid Arthritis
13.5.3. Diabetes
13.5.4. Anaphylaxsis
13.5.5. Others
13.6. Market Value Forecast, by End-user, 2017-2031
13.6.1. Homecare Settings
13.6.2. Hospitals & Clinics
13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Type
13.8.2. By Technology
13.8.3. By Route of Administration
13.8.4. By Indication
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Autoinjectors Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
14.2.1. Disposable
14.2.2. Reusable
14.3. Market Value Forecast, by Technology, 2017-2031
14.3.1. Handheld
14.3.2. Wearable
14.4. Market Value Forecast, by Route of Administration, 2017-2031
14.4.1. Subcutaneous
14.4.2. Intramuscular
14.5. Market Value Forecast, by Indication, 2017-2031
14.5.1. Multiple Sclerosis
14.5.2. Rheumatoid Arthritis
14.5.3. Diabetes
14.5.4. Anaphylaxsis
14.5.5. Others
14.6. Market Value Forecast, by End-user, 2017-2031
14.6.1. Homecare Settings
14.6.2. Hospitals & Clinics
14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Type
14.8.2. By Route of Administration
14.8.3. By Technology
14.8.4. By Indication
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Autoinjectors Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017-2031
15.2.1. Disposable
15.2.2. Reusable
15.3. Market Value Forecast, by Technology, 2017-2031
15.3.1. Handheld
15.3.2. Wearable
15.4. Market Value Forecast, by Route of Administration, 2017-2031
15.4.1. Subcutaneous
15.4.2. Intramuscular
15.5. Market Value Forecast, by Indication, 2017-2031
15.5.1. Multiple Sclerosis
15.5.2. Rheumatoid Arthritis
15.5.3. Diabetes
15.5.4. Anaphylaxsis
15.5.5. Others
15.6. Market Value Forecast, by End-user, 2017-2031
15.6.1. Homecare Settings
15.6.2. Hospitals & Clinics
15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Type
15.8.2. By Technology
15.8.3. By Route of Administration
15.8.4. By Indication
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Autoinjectors Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Type, 2017-2031
16.2.1. Disposable
16.2.2. Reusable
16.3. Market Value Forecast, by Technology, 2017-2031
16.3.1. Handheld
16.3.2. Wearable
16.4. Market Value Forecast, by Route of Administration, 2017-2031
16.4.1. Subcutaneous
16.4.2. Intramuscular
16.5. Market Value Forecast, by Indication, 2017-2031
16.5.1. Multiple Sclerosis
16.5.2. Rheumatoid Arthritis
16.5.3. Diabetes
16.5.4. Anaphylaxsis
16.5.5. Others
16.6. Market Value Forecast, by End-user, 2017-2031
16.6.1. Homecare Settings
16.6.2. Hospitals & Clinics
16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Type
16.8.2. By Technology
16.8.3. By Route of Administration
16.8.4. By Indication
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2022)
17.3. Company Profiles
17.3.1. Ypsomed Holding AG
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. Novartis AG
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.4. Recent Developments
17.3.3. BD
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. Medmix Healthcare
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. Eli Lilly and Company
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. Sanofi
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. Mylan N.V.
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. Amgen Inc.
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. SHL Medical AG
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. Recipharm AB
17.3.10.1. Company Overview
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Business Strategies
17.3.10.5. Recent Developments
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/